Short-term safety evaluation of intraperitoneal chemotherapy with Raltitrexed for colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2019.03.006

Abstract

Abstract:

Objective

To evaluate of the recent safety and feasibility of intraoperative intraperitoneal chemotherapy with Raltitrexed for colorectal cancer patients.

Methods

The clinical data of colorectal cancer patients undergoing surgery from the National Cancer Center from July 2017 to October 2018 were retrospectively analyzed. 80 colorectal cancer patients who underwent radical surgery were divided into two groups. The Raltitrexed group (40 patients), who received intraoperative intraperitoneal perfusion chemotherapy with Raltitrexed and the control group (40 patients), who did not receive intraoperative intraperitoneal perfusion chemotherapy. Analysis of the recent safety differences between the two groups in terms of postoperative complications, liver and kidney function, hematological toxicity, and time of gastrointestinal function recovery.

Results

There was no significant differences in the incidence of postoperative complications, liver and kidney function, blood toxicity and recovery time of gastrointestinal function between the two groups (all P>0.05).

Conclusions

Intraoperative perfusion with Raltitrexed for patients with colorectal cancer has good safety and tolerability, and does not increase postoperative complications.

Key words: Colorectal neoplasms, Surgery, Raltitrexed, Intraperitoneal perfusion chemotherapy, Safety

Jianan Chen, Zheng Wang, Along Zhang, Zheng Liu, Haiyu Shen, Zhijie Wang, Fuqiang Zhao, Shiwen Mei, Qian Liu. Short-term safety evaluation of intraperitoneal chemotherapy with Raltitrexed for colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2019, 08(03): 241-245.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2019.03.006

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2019/V08/I03/241

Figures/Tables 3

References 21

[1]	Chen H, Li N, Ren J, et al. Participation and yield of a population-based colorectal cancer screening programme in China [J]. Gut, 2018, 2018-317124.
[2]	Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer [J]. British Journal of Surgery, 2012, 99(5): 699-705.
[3]	Augestad KM, Bakaki PM, Rose J, et al. Metastatic spread pattern after curative colorectal cancer surgery. A retrospective, longitudinal analysis [J]. Cancer Epidemiology, 2015, 39(5): 734-744.
[4]	van Gestel YRBM, Thomassen I, Lemmens VEPP, et al. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer [J]. European Journal of Surgical Oncology (EJSO), 2014, 40(8): 963-969.
[5]	Koppe MJ, Boerman OC, Oyen WJG, et al. Peritoneal Carcinomatosis of Colorectal Origin [J]. Annals of Surgery, 2006, 243(2): 212-222.
[6]	Pamela K, Matthias Z, Reinhold KR, et al. Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): a Single-Center Experience in Austria [J]. Journal of Gastrointestinal Surgery, 2018, 22(3): 1-10.
[7]	Ying H. The progression of exploratory development of raltitrexed in colorectal cancer [J]. Journal of Modern Oncology, 2012, 27(3): 276-285.
[8]	Bendavid Y, Leblond F. A study of the effect of temperature on the pharmacokinetic profile of raltitrexed administered by intraperitoneal route in the rat [J]. Medical Science Monitor International Medical Journal of Experimental & Clinical Research, 2005, 11(1): 1-5.
[9]	Nguyen D, Emond C, Leclerc Y, et al. Pharmacokinetics studies and toxicity profile of raltitrexed used by intraperitoneal route in normothermia in a pig model [J]. Medical Science Monitor International Medical Journal of Experimental & Clinical Research, 2003, 9(1): R37-R42.
[10]	Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer [J]. Br J Surg, 2012, 99(5): 699-705.
[11]	Verwaal VJ, Bruin S, Boot H, et al. 8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer [J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 2003, 21(20): 3737-3743.
[12]	Gestel YRBM, Thomassen I, Lemmens VEPP, et al. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer [J]. European Journal of Surgical Oncology the Journal of the European Society of Surgical Oncology & the British Association of Surgical Oncology, 2014, 40(8): 963-969.
[13]	Solomon MJ, Egan M, Roberts RA, et al. Incidence of free colorectal cancer cells on the peritoneal surface [J]. Diseases of the Colon & Rectum, 1997, 40(11): 1294.
[14]	Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-ynecologic malignancies [J]. Cancer, 2000, 88(2): 358-363.
[15]	Hompes D, Tiek J, Wolthuis A, et al. HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome? [J]. Annals of Oncology Official Journal of the European Society for Medical Oncology, 2012, 23(12): 3123.
[16]	Sugarbaker PH. Colorectal Cancer: Prevention and Management of Metastatic Disease [J]. Biomed Res Int, 2014, 2014(2): 782890.
[17]	Pohlen U, Rieger H, Kunick-Pohlen S, et al. Phase II study of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome [J]. Anticancer Research, 2007, 27(1B): 667-674.
[18]	Reema H, Vanessa S, Olga U, et al. Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy [J]. Anz Journal of Surgery, 2010, 76(3): 156-161.
[19]	王雪玮, 周海涛, 王锡山. 结直肠癌术中腹腔化疗专家意见(2017版) [J/CD]. 中华结直肠疾病电子杂志, 2017, 6(6): 442-446.
[20]	苏昊, 周海涛, 王锡山, 等. 洛铂用于结直肠癌术中腹腔灌洗化疗的近期疗效分析[J/CD]. 中华结直肠疾病电子杂志, 2018, 7(2): 125-129.
[21]	Ping Z, Zhi D, Tang L, et al. Preliminary investigation of intraperitoneal raltitrexed in patients with gastric cancer [J]. World Journal of Surgical Oncology, 2014, 12(1): 1-7.

变量		研究组（n=40）	对照组（n=40）	检验值	P值
年龄（岁）		58.7±9.0	59.8±8.9	0.356	0.57
性别		?	?	0.373	0.815
?	（男/女）	27/13	25/15	?	?
新辅助治疗		?	?	0.405	0.754
?	（是/否）	5/35	7/33	?	?
分化程度		?	?	0.59	0.761
?	低分化	3	4	?	?
?	中低分化	15	15	?	?
?	中分化	19	20	?	?
?	高分化	3	1	?	?
临床分期		?	?	0.121	0.644
?	Ⅱ期	14	16	?	?
?	Ⅲ期	26	24	?	?
肿瘤部位		?	?	0.285	0.23
?	右半结肠	7	9	?	?
?	左半结肠	4	2	?	?
?	乙状结肠	4	10	?	?
?	直肠	25	19	?	?

变量		研究组（n=40）	对照组（n=40）	检验值	P值
年龄（岁）		58.7±9.0	59.8±8.9	0.356	0.57
性别		?	?	0.373	0.815
?	（男/女）	27/13	25/15	?	?
新辅助治疗		?	?	0.405	0.754
?	（是/否）	5/35	7/33	?	?
分化程度		?	?	0.59	0.761
?	低分化	3	4	?	?
?	中低分化	15	15	?	?
?	中分化	19	20	?	?
?	高分化	3	1	?	?
临床分期		?	?	0.121	0.644
?	Ⅱ期	14	16	?	?
?	Ⅲ期	26	24	?	?
肿瘤部位		?	?	0.285	0.23
?	右半结肠	7	9	?	?
?	左半结肠	4	2	?	?
?	乙状结肠	4	10	?	?
?	直肠	25	19	?	?

变量		研究组（n=40）	对照组（n=40）	检验值	P值
手术方式		?	?	0.000	1
?	腹腔镜	38	37	?	?
?	开腹	2	3	?	?
术后并发症		?	?	?	?
?	发热	3	2	0.000	1
?	恶心、呕吐	30	26	0.087	0.464
?	切口感染	2	3	0.000	1
?	肠梗阻	2	2	0.000	1
?	吻合口漏	1	1	0.000	1
?	吻合口出血	1	1	0.000	1
?	再次手术	2	1	0.000	1
排气时间（天）		2.97±1.22	2.87±1.58	-0.295	0.754

变量		研究组（n=40）	对照组（n=40）	检验值	P值
手术方式		?	?	0.000	1
?	腹腔镜	38	37	?	?
?	开腹	2	3	?	?
术后并发症		?	?	?	?
?	发热	3	2	0.000	1
?	恶心、呕吐	30	26	0.087	0.464
?	切口感染	2	3	0.000	1
?	肠梗阻	2	2	0.000	1
?	吻合口漏	1	1	0.000	1
?	吻合口出血	1	1	0.000	1
?	再次手术	2	1	0.000	1
排气时间（天）		2.97±1.22	2.87±1.58	-0.295	0.754

变量			研究组（n=40）	对照组（n=40）	t值	P值
血细胞分析			?	?	?	?
?	红细胞水平（×10⁹/L）		?	?	?	?
?	?	术前	120.0±32.9	122.8±27.2	1.256	0.842
?	?	术后	106.6±25.3	103.0±23.2	0.877	0.746
?	白细胞水平（×10⁹/L）		?	?	?	?
?	?	术前	6.1±2.2	6.3±1.4	-1.854	0.732
?	?	术后	6.9±2.4	8.0±3.1	0.615	0.345
?	血小板水平（×10⁹/L）		?	?	?	?
?	?	术前	312.9±94.7	309.9±107.9	0.325	0.941
?	?	术后	214.9±91.9	228.3±79.3	-0.649	0.695
肾功能			?	?	?	?
?	血尿素氮（mmol/L）		?	?	?	?
?	?	术前	4.1±1.2	4.5±1.3	0.497	0.353
?	?	术后	4.8±1.4	5.4±1.8	0.836	0.399
?	肌酐（μmol/L）		?	?	?	?
?	?	术前	68.7±13.2	76.2±15.6	2.257	0.202
?	?	术后	58.9±16.0	70.2±17.3	-1.472	0.097
肝功能			?	?	?	?
?	ALT（U/L）		?	?	?	?
?	?	术前	20.9±15.4	29.5±35.1	1.525	0.426
?	?	术后	36.1±70.2	34.1±81.8	1.616	0.947

Please choose a citation manager

Content to export